Novel Antischizophrenia Treatments

Front Cover
Mark A. Geyer, Gerhard Gross
Springer Science & Business Media, Oct 1, 2012 - Medical - 458 pages
0 Reviews
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

Behavioral Animal Models to Assess Procognitive Treatments for Schizophrenia
39
Towards MedicationEnhancement of Cognitive Interventions in Schizophrenia
80
Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment
113
5HT2C Agonists as Therapeutics for the Treatment of Schizophrenia
146
The Role of Dopamine D3 Receptors in Antipsychotic Activity and Cognitive Functions
167
Nicotinic Mechanisms in the Treatment of Psychotic Disorders A Focus on the α7 Nicotinic Receptor
211
Muscarinic Mechanisms in Psychotic Disorders
233
Glutamatergic Synaptic Dysregulation in Schizophrenia Therapeutic Implications
266
Metabotropic Glutamate Receptors for New Treatments in Schizophrenia
297
Glycine Transport Inhibitors in the Treatment of Schizophrenia
366
Nicotinic Receptors and Functional Regulation of GABA Cell Microcircuitry in Bipolar Disorder and Schizophrenia
401
Development of DiseaseModifying Treatment of Schizophrenia
418
Index
443
Copyright

Other editions - View all

Common terms and phrases

Bibliographic information